Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing proprietary drug candidates for central nervous system diseases. Its lead candidate, roluperidone, is being developed to treat negative symptoms in people with schizophrenia; the company plans a confirmatory Phase 3… From the company’s description.
In fiscal 2025, Minerva Neurosciences, Inc. reported a net loss of $293.42M. Operations used $13.51M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Minerva Neurosciences, Inc. does
In the company’s own words
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing proprietary drug candidates for central nervous system diseases. Its lead candidate, roluperidone, is being developed to treat negative symptoms in people with schizophrenia; the company plans a confirmatory Phase 3 trial to support a potential resubmission of its U.S. drug application. Roluperidone may also be studied for other conditions, including apathy in dementia, Alzheimer’s disease, Parkinson’s disease and depression. Minerva previously co-developed seltorexant with Janssen for insomnia and major depressive disorder, then sold its rights to potential royalties to Royalty Pharma in 2021. The company has no approved products and has not generated revenue from product sales or licensing. It operates as a single clinical-stage business rather than reporting separate operating segments, and relies on contract manufacturers and clinical research partners. For 2025, Minerva reported total operating expenses of $293.4 million. Its website is www.minervaneurosciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 1598646
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Minerva Neurosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Minerva Neurosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Minerva Neurosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Minerva Neurosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Minerva Neurosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”